Edwards Lifesciences (NYSE:EW) this week updated on a slew of European patent spats against Boston Scientific (NYSE:BSX) over heart valves, expecting to hear responses from both German and U.K. courts within the 1st half of 2017.
The company said it filed a lawsuit against Sadra Medical and Boston Scientific in Nov. 2, 2015, seeking to invalidate and revoke patents related to heart valve technology. Boston Scientific and its subsidiaries filed counterclaims, alleging that Edwards Sapien 3 infringed upon their own patents.
Edwards said that the trial over the patents was held in January, and that the company is expecting a decision in the 1st half of 2017.
In Nov. 2015, Edwards filed a separate infringement suit against Boston Scientific claiming similar patent infringements related to the Lotus valve. The company is seeking unspecified monetary damages and injunctive release.
The company said that a trial was held on the patent issues this month, and that it expects a response from the German district court during the 1st quarter of 2017, according to an SEC filing.
Last November, a federal judge in Massachusetts added $21 million to the $70 million Neovasc (NSDQ:NVCN) owes Edwards Lifesciences subsidiary CardiAQ Valve in their spat over replacement heart valve technology.
A jury in May awarded $70 million to CardiAQ after finding that Neovasc misappropriated trade secrets in developing its Tiara transcatheter mitral valve replacement device. Edwards inherited the lawsuit when it acquired CardiAQ Valve for $400 million in August 2014.
The post Edwards, Boston Scientific await EU court decisions in heart valve patent spats appeared first on MassDevice.
from MassDevice http://ift.tt/2lsEiVD
Cap comentari:
Publica un comentari a l'entrada